Literature DB >> 15808665

Bile duct exclusion from selective vascular inflow occlusion in rat liver: role of ischemic preconditioning and N-acetylcysteine on hepatic reperfusion injury.

E F S Montero1, C Quireze, D M R d'Oliveira.   

Abstract

AIM: To study the effects of N-acetylcysteine and ischemic preconditioning on the portal triad clamping compared to arterial and portal clamping alone.
METHODS: Eighty EPM 1-Wistar rats were randomized into two groups, depending on inclusion (Group 1) or not (Group 2) of the bile duct in the hepatic vascular pedicle occlusion. Each group was divided into four subgroups as follows. IR 1: 20 minutes after celiotomy, the pedicle containing vascular elements and bile duct to the left lateral and median liver lobes was occluded for 40 minutes, followed by 30 minutes of reperfusion. IPC 1: after 10 minutes of ischemia and 10 minutes of reperfusion, the ischemic preconditioning period, the rats were submitted to the same procedure described for IR 1 Group. NAC 1: the rats received N-acetylcysteine (150 mg/kg) 15 minutes before 40 minutes of ischemia and 5 minutes before 30 minutes of reperfusion. SHAM 1: The hepatic pedicle for the lateral and median liver lobes was dissected after 20 minutes, the bile duct alone was clamped for 40 minutes, and released for an additional 30 minutes. In the IR 2, IPC 2, and NAC 2 groups, ischemia was achieved with an exclusive vascular occlusion. SHAM 2: dissection and observation for 90 minutes. The blood was sampled for liver enzyme levels. Statistical analysis was done (P </= .05).
RESULTS: Hepatic IR injury was less severe for animals from the classic portal triad clamping (group 1), with regard to AST (IR 1 Group 766 vs IR 2 Group 1380 U/L) and ALT (IR 1 Group 840 vs IR 2 Group 1576 U/L); IPC, but not NAC administration, was able to protect the liver from IR injury for animals from the classic portal triad clamping group, with regard to AST (IPC 1 Group 421 vs NAC 1 Group 1131 U/L) and ALT (IPC 1 Group 315 vs NAC 1 Group 1085 U/L).
CONCLUSIONS: IPC protects the liver from IR injury; classic portal triad clamping results in a less severe hepatic IR injury when compared to bile duct exclusion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808665     DOI: 10.1016/j.transproceed.2004.12.194

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Multidrug donor preconditioning prevents cold liver preservation and reperfusion injury.

Authors:  Mohammed Reza Moussavian; Claudia Scheuer; Michael Schmidt; Otto Kollmar; Matthias Wagner; Maximilian von Heesen; Martin K Schilling; Michael D Menger
Journal:  Langenbecks Arch Surg       Date:  2010-06-27       Impact factor: 3.445

Review 2.  Experimental and clinical evidence for modification of hepatic ischaemia-reperfusion injury by N-acetylcysteine during major liver surgery.

Authors:  Santhalingam Jegatheeswaran; Ajith K Siriwardena
Journal:  HPB (Oxford)       Date:  2011-02       Impact factor: 3.647

3.  Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model.

Authors:  Eliza W Beal; Curtis Dumond; Jung-Lye Kim; Khalid Mumtaz; Don Hayes; Ken Washburn; Bryan A Whitson; Sylvester M Black
Journal:  J Vis Exp       Date:  2017-04-02       Impact factor: 1.355

4.  Evaluation of potential changes in liver and lung tissue of rats in an ischemia-reperfusion injury model (modified pringle maneuver).

Authors:  Silvio Henrique Freitas; Renata G S Dória; Rachel S Bueno; William B Rocha; Jair R E Filho; Julieta R E Moraes; Atanásio Serafin Vidane; Carlos E Ambrósio
Journal:  PLoS One       Date:  2017-06-12       Impact factor: 3.240

5.  Melatonin treatment of pigs with acute pancreatitis reduces inflammatory reaction of pancreatic tissue and enhances fitness score of pigs: experimental research.

Authors:  Katharina Grupp; Johannes Erbes; Annika Poppe; Karin Wodack; Andreas Gocht; Constantin Trepte; Jan Havel; Oliver Mann; Jakob R Izbicki; Kai Bachmann
Journal:  World J Emerg Surg       Date:  2019-04-11       Impact factor: 5.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.